Prot #BAY 1436032/19036: An open-label, non-randomized, multicenter Phase I study to determine the maximum tolerated and/or recommended Phase II dose of oral mutant IDH1 (mIDH1) inhibitor BAY 1436032 and to characterize its safety, tolerability, pharmacok

Project: Research project

Project Details

Effective start/end date2/22/186/1/19


  • Covance Inc. (Prot #BAY 1436032/19036)
  • Bayer HealthCare Pharmaceuticals, Inc. (Prot #BAY 1436032/19036)